 SAN DIEGO, July 25, 2022 GLOBE NEWSWIRE -- Fate Therapeutics, Inc. the Company or Fate Therapeutics NASDAQ: FATE, a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 3, 2022 at 5:00 PM ET to report its second quarter 2022 financial results and provide a corporate update. 